Polio Vaccines Market 2026 | Global Analysis, Latest Industry Trends, Recasts Revenue Growth At Global & Country Level, Size, Share, Demand, Challenges And Sub-Segments From 2019 To 2026

Polio Vaccines Market – Insights

Poliovirus causes a highly infectious disease, poliomyelitis, also known as polio or infantile paralysis. The virus belongs to genus Enterovirus – a single-stranded RNA virus and can be divided into three serotypes: P1, P2, and P3. Immunity to one serotype does mean immunity to other two serotypes. The primary source of transmission for poliovirus is fecal-oral route, by ingesting contaminated food or water. Oral-oral route can also transmit the virus. People infected from the virus may spread the disease for up to six weeks without any symptoms. The virus majorly resides in the gastrointestinal tract, specifically intestine and oropharynx. It attacks local lymphoid tissue and enters bloodstream, thereby infecting cells of the central nervous system (CNS). The virus multiplies in the motor neurons of the anterior horn and brain stem, which may lead to destruction of cells. This leads to typical manifestations of polio.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/380

Polio Vaccines Market: Drivers

Poliomyelitis is more common in children under five years of age and around 70% of all the infections have no symptoms. Moreover, 25-30% of infections in children may lead to nonspecific illness without clinical or laboratory evidence of invasion on the CNS. Therefore, increasing focus of government and private organizations on vaccination with prophylactic approach for prevention of polio is expected to boost growth of the global polio vaccines market over the forecast period.

The market growth is driven by the fact that around 1% of polio cases can lead to paralytic polio which causes paralysis in the spinal cord (spinal polio), brainstem (bulbar polio), or both (bulbospinal polio). According to the World Health Organization (WHO), 1 in 200 infections leads to irreversible paralysis. Among those paralyzed, 5% to 10% die when their breathing muscles become immobilized. Moreover, according to the WHO, polio cases have decreased by over 99% since 1988, from an estimated 350,000 cases then, to 74 reported cases in 2015. The reduction is the result of the global effort to eradicate the disease. Of the 3 serotypes, P2 was eradicated in 1999 and number of cases of P3 has decreased significantly.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/380

Increasing focus on eliminating both wild and vaccine-derived polio incidence is expected to contribute to growth of the market. Since 2000, UNICEF OPV procurement has averaged 1.8 Bn doses, annually. Global Polio Eradication Initiative (GPEI) launched the “End Game Strategic Plan 2013-2018” at the World Health Assembly in May 2013. This comprehensive strategy focuses on eliminating both wild and vaccine-derived polio incidence through routine immunization programs, thereby gradually replacing OPV use with IPV vaccine.

There are two types of vaccine that protect against polio:

• Inactivated poliovirus vaccine (IPV): given as an injection.
• Oral poliovirus vaccine (OPV): given orally

Although OPV has not been used in the U.S. since 2000, it is still used in other countries. IPV is still available in the U.S.

Polio Vaccines Market: Taxonomy 

Polio vaccines market is segmented on the basis of product type, end user, and region:

By Product Type:

• IPV
• OPV

By End User:

• Hospital
• Clinics
• Public Services
• Others

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/polio-vaccines-market-380

Polio Vaccines Market: Restraints

Decreasing cases of polio is expected to hinder growth of the market.  For instance, the U.S. declared polio-free in 1994 and Australia, China, and other 37 Pacific countries in 2004. In India, no cases of wild polio infections have been recorded since 2011. Moreover, only three countries: Afghanistan, Nigeria, and Pakistan have cases of wild polio infections, which may aid in growth of the market.

Indigenous wild poliovirus type 2 has not been detected since 1999. In 2015, the World Health Assembly agreed that all Member States that currently use OPV should prepare for the global withdrawal of the type 2 component of OPV in April 2016. According to WHO, member countries are required to introduce at least 1 dose of the IPV into routine immunization schedule.

Polio Vaccines Market: Competitive Landscape

Sanofi Pasteur and Bilthoven Biologicals/ Serum Institute of India are the 2 companies which was awarded in 2014 by UNICEF for the supply of IPV in 1, 5 and 10 dose vials, and long term supply agreements were established through to 2018. According to UNICEF report, Bio Farma (Indonesia), GlaxoSmithKline (GSK) (UK) and Sanofi Pasteur (France) are the only OPV bulk manufacturers. Novartis (Switzerland) has stopped their manufacture of OPV. Other market players include, Sinovac Biotech Ltd., IPOLand Aventis Pasteur, Merck & Co., Bibcol, Pfizer, Beijing Tiantan Biological, Bio-Med, Panacea Biotec Ltd., and Adithya Vaccine Pharma.

Table of Content

Global Polio Vaccines Market Research Report
Section 1: Global Polio Vaccines Industry Overview
Section 2: Global Economic Impact on Polio Vaccines Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Polio Vaccines Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Polio Vaccines Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837